COMP <GO>
NNNN vs ICCC // FORWARD P/E MULTIPLE
Anbio Biotechnology (Class A) (NASDAQ) VS. ImmuCell Corporation (NASDAQ) • 15-METRIC TALLY: NNNN 6
— ICCC 4
■ METRIC PARITY
LAST: $3.72 (-3.12%) • MKT CAP: $535.3M
forward-pe
77.7x
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. ICCC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | ICCC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 41.40% | +45.80 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | 4.20% | +12.80 | NNNN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | 35.9x | +55.60 | ICCC | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | 1.31% | -2.57 | ICCC | /fcf-yield <GO> |
| Operating Margin | 66.70% | 6.00% | +60.70 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -3.80% | +71.80 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 4.30% | +1.30 | NNNN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.28 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | ICCC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.9 | 51.8 | -13.90 | ICCC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 77.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $93.7M | $441.5M | NNNN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | ICCC REV | NNNN GROSS % | ICCC GROSS % | NNNN FCF | ICCC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $27.6M | 87.2% | 41.4% | -$6.7M | $1.2M |
| FY 2024 | $8.2M | $26.5M | 71.9% | 30.0% | $2.1M | -$107.8K |
| FY 2023 | $6.7M | $17.5M | — | — | $898.4K | -$4.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
ICCC // BETA —